Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Reduced CCR5 expression among Uganda HIV controllers

View through CrossRef
Abstract Background Several mechanisms including reduced CCR5 expression, protective HLA, viral restriction factors, broadly neutralizing antibodies, and more efficient T-cell responses, have been reported to account for HIV control among HIV controllers. However, no one mechanism universally accounts for HIV control among all controllers. In this study we determined whether reduced CCR5 expression accounts for HIV control among Ugandan HIV controllers. We determined CCR5 expression among Ugandan HIV controllers compared with treated HIV non-controllers through ex-vivo characterization of CD4 + T cells isolated from archived PBMCs collected from the two distinct groups. Results The percentage of CCR5 + CD4 + T cells was similar between HIV controllers and treated HIV non-controllers (ECs vs. NCs, P = 0.6010; VCs vs. NCs, P = 0.0702) but T cells from controllers had significantly reduced CCR5 expression on their cell surface (ECs vs. NCs, P = 0.0210; VCs vs. NCs, P = 0.0312). Furthermore, we identified rs1799987 SNP among a subset of HIV controllers, a mutation previously reported to reduce CCR5 expression. In stark contrast, we identified the rs41469351 SNP to be common among HIV non-controllers. This SNP has previously been shown to be associated with increased perinatal HIV transmission, vaginal shedding of HIV-infected cells and increased risk of death. Conclusion CCR5 has a non-redundant role in HIV control among Ugandan HIV controllers. HIV controllers maintain high CD4 + T cells despite being ART naïve partly because their CD4 + T cells have significantly reduced CCR5 densities.
Title: Reduced CCR5 expression among Uganda HIV controllers
Description:
Abstract Background Several mechanisms including reduced CCR5 expression, protective HLA, viral restriction factors, broadly neutralizing antibodies, and more efficient T-cell responses, have been reported to account for HIV control among HIV controllers.
However, no one mechanism universally accounts for HIV control among all controllers.
In this study we determined whether reduced CCR5 expression accounts for HIV control among Ugandan HIV controllers.
We determined CCR5 expression among Ugandan HIV controllers compared with treated HIV non-controllers through ex-vivo characterization of CD4 + T cells isolated from archived PBMCs collected from the two distinct groups.
Results The percentage of CCR5 + CD4 + T cells was similar between HIV controllers and treated HIV non-controllers (ECs vs.
NCs, P = 0.
6010; VCs vs.
NCs, P = 0.
0702) but T cells from controllers had significantly reduced CCR5 expression on their cell surface (ECs vs.
NCs, P = 0.
0210; VCs vs.
NCs, P = 0.
0312).
Furthermore, we identified rs1799987 SNP among a subset of HIV controllers, a mutation previously reported to reduce CCR5 expression.
In stark contrast, we identified the rs41469351 SNP to be common among HIV non-controllers.
This SNP has previously been shown to be associated with increased perinatal HIV transmission, vaginal shedding of HIV-infected cells and increased risk of death.
Conclusion CCR5 has a non-redundant role in HIV control among Ugandan HIV controllers.
HIV controllers maintain high CD4 + T cells despite being ART naïve partly because their CD4 + T cells have significantly reduced CCR5 densities.

Related Results

HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
OSPHL in collaboration with APHL, will evaluate the performance of the Oxford Nanopore Technology sequencers for HIV genome sequencing using a modified protocol of the ARTIC amplic...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract Introduction Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
JAK/STAT signaling pathway affects CCR5 expression in human CD4 + T cells
JAK/STAT signaling pathway affects CCR5 expression in human CD4 + T cells
CCR5 serves as R5-tropic HIV co-receptor. Knocking out CCR5 in HIV patients, which has occurred <10 times, is believed important for cure. JAK/STAT inhibitors tofacitinib and ru...
CCR5-Δ32 gene variant frequency in the Nigerian and Zimbabwean populations living in North Cyprus
CCR5-Δ32 gene variant frequency in the Nigerian and Zimbabwean populations living in North Cyprus
Background: The cystine-cystine chemokine receptor 5 (CCR5) is the primary HIV co-receptor involved in the viral entry process into human cells. The 32 bp deletion variant within t...
Exploring CCR5 + T regulatory cell subset dysfunction in type 1 diabetes patients: implications for immune regulation
Exploring CCR5 + T regulatory cell subset dysfunction in type 1 diabetes patients: implications for immune regulation
Abstract T regulatory lymphocytes (Treg) expressing CCR5 exhibit strong suppression activity in various autoimmune disorders. However, there remains a lack of com...
Evaluation of CCR5 inhibition in breast cancer using novel, potent inhibitors
Evaluation of CCR5 inhibition in breast cancer using novel, potent inhibitors
Background: Targeting the chemokine CCL5 and its receptor CCR5 has emerged as a promising strategy in the treatment of breast cancer. Different approaches are studied today to inhi...
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
HIV cross-sectional surveys require multi-layered testing with several tests to estimate HIV prevalence and HIV-1 incidence. We evaluated the performance and accuracy of the newly ...

Back to Top